IRCT20111206008307N45
Recruiting
Phase 3
Evaluation Effects of Dapagliflozin and Empagliflozin in Nondiabetic Patients with Left Ventricular Systolic Dysfunction following ST Elevation Myocardial Infarction : A Randomized Clinical Trial
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tabriz University of Medical Sciences
- Enrollment
- 75
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Heart Failure with Reduced Ejection Fraction
- •Aged 18 to 80 years
- •Consented patients
Exclusion Criteria
- •Liver failure
- •Renal failure (estimated glomerular filtration rate less than 30 ml/min)
- •Patients with a history of taking dapagliflozin or empagliflozin
- •Diabetes mellitus
- •Contraindications of dapagliflozin or empagliflozin
- •Inflammatory and autoimmune diseases
- •Systolic blood pressure less than 100 or more than 180 mm Hg
- •Symptomatic hypotension
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trialtype 2 diabetes mellitus, NAFLD, NASHJPRN-UMIN000030548Saitama Medical University Hospital100
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Not yet recruiting
Phase 4
Comparison of Dapagliflozin and Pioglitazone for Non-Alcoholic Fatty Liver Disease in Type 2 DiabetesHealth Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2024/07/071087Babra
Completed
Not Applicable
A study to learn more about how dapagliflozin affects body fat levels compared to glimepiride in patients with type 2 diabetes who are taking metformiEndocrine, nutritional and metabolic diseaseKCT0003600AstraZeneca Korea160
Not yet recruiting
Not Applicable
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R